Switzerland-based drugs company Debiopharm Group has led a $3m series A round in Spinomix, a local diagnostics company.
Undisclosd existing investors and a private US investor group were also in the round, Debiopharm said.
Founded in 2004 and located at the Swiss Federal Institute of Technology of Lausanne (EPFL), Lausanne, Spinomix helps with sample preparation of biological materials.
Thierry Mauvernay, delegate of Debiopharm’s board, said: “At a time where all healthcare players are expected to contribute to keeping healthcare cost under control, Debiopharm has been impressed by Spinomix MagPhase and FibroTrap platforms, their ease of use and huge potential for cost effective solutions.”